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Summary The influence of pretreatment serum neuron-specific enolase (S-NSE) in addition to more
conventional prognostic factors on survival duration in small-cell lung cancer (SCLC) was investigated in 770
patients from nine centres in six countries. The other variables included stage of disease, performance status
(PS), age, sex, serum lactate dehydrogenase (S-LDH), serum alkaline phosphatase (S-AP), and serum
carcinoembryonic antigen (S-CEA). Increased values of S-NSE (> 12.5 jig-' 1) were observed in 81% of the
patients, whereas S-LDH, S-AP and S-CEA were elevated in only half of the patients or less. Multivariable
analysis by Cox's proportional hazard model disclosed S-NSE as the most powerful prognostic factor followed
by poor PS and extensive stage disease. If PS was ignored, S-LDH came up as a significant prognostic factor.
S-AP, S-CEA, age and sex had no significant influence on the prognosis. The three prognostic factors, S-NSE,
PS and stage of disease, enabled establishment of a prognostic index (PI) based on a simple algorithm
PI ZNSE+Zstage+2zps. This segregated the patients into four groups with clearly different prognosis. The
median survival and 95% confidence intervals of the four groups were: 468 days (540-408), 362 days (405-
328), 256 days (270-241) and 125 days (179-58). Based on the present results we recommend S-NSE and PS,
in addition to stage, for prognostic stratification in treatment trials on SCLC.
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Treatment outcome in cancers with short survival is usually
recorded as an improvement of the prognosis. In small-cell
lung cancer (SCLC) some of the first identified prognostic
factors were performance status (PS) and disease extent
(Edmonson et al., 1976; Cohen et al., 1979; Ihde et al., 1981),
both still recognised as clinically useful determinants of the
prognosis. Later on, the influence from biochemical variables
was stressed (Cohen et al., 1981). In itself these continuous
variables are more exact than stage of disease, which depends
on the choice and sensitivity of staging procedures, and PS,
which is the result of a rather rough individual estimate.
In selection of candidate prognostic factors the influence
on survival is most important, but the size of the fraction of
patients with a positive test also plays a role (Rawson and
Peto, 1990). In SCLC pretreatment serum neuron-specific
enolase (S-NSE) has both qualities. In a series of studies
pretreatment S-NSE was found to be increased in 80% of
patients. (Akoun et al., 1985; Cooper et al., 1985; Harding et
al., 1990). In two multivariate studies S-NSE proved to be a
prominent prognostic factor together with strong factors such
as PS and stage of disease (J0rgensen et al., 1988; Johnson et
al., 1993). S-NSE was positively correlated to serum lactate
dehydrogenase (S-LDH), and the influence on survival of S-
NSE was correlated to that of the concomitant S-LDH, and
both correlated to stage of disease. Several multivariate
analyses including routine laboratory data, PS and disease
stage have proved that reasonable prognostic stratification is
possible without inclusion of stage in the stratification
algorithm (Souhami et al., 1985; 0sterlind et al., 1986). In
a review on data from 3873 patients from ten centres
(Rawson et al., 1990), PS and serum alkaline phosphatase (S-
AP) were both strong prognostic predictors. S-AP might be
substituted by S-LDH, which was, however, only available
from a minority of the ten centres. An index based on PS,
stage of disease and S-AP or S-LDH as indicators of
extensive disease was advocated.
To elucidate further the influence of S-NSE and S-LDH
on prognosis a retrospective multicentre study was carried
out. The aim was to evaluate the prognostic influence of S-
NSE and S-LDH in conjunction with other important
prognostic factors such as disease stage and PS, to reassess
the previously identified important categorisation of contin-
uous variables, and, ifpossible, to establish a simple powerful
prognostic index. Centres, which had published on S-NSE in
SCLC, were contacted and original data were gathered for a
combined, multivariable analysis.
Material and methods
Patients and data
Data on 787 patients with small-cell lung cancer were
supplied from nine centres in six countries. Inclusion criteria
were histologically proven SCLC, data on pretreatment
values of S-NSE and S-LDH including methods of the
analyses and reference limits plus data on age, sex, disease
stage and PS. Stage was classified as limited or extensive
disease (LD, ED) according to conventional criteria (WHO,
1982). Patients without S-LDH measurements but with S-AP
or serum carcinoembryonic antigen (S-CEA) measurements
were accepted. Performance status scored according to the
WHO/ECOG system was transformed to Karnofsky
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(Karnofsky, 1949) scale values after the guidelines in Table I.
Survival data in weeks or months were converted into days
by multiplication with 7 and 30 respectively.
Assays
The RIA-NSE assay from Pharmacia, Sweden, was used in
all but two centres, which used corresponding methods. The
upper reference limit of S-NSE based on measurements in
healthy persons was 12.5 jug I1 at all nine centres. There was
more variation from centre to centre in the methods used for
analysis of S-LDH, S-AP and S-CEA. All marker values were
normalised by division with the upper reference limit of the
marker at the individual centre. The integer part of the
resulting figures could thus be regarded as a factor of
increase.
Statistical analyses
The prognostic impact of the pretreatment variables
summarised above was investigated by use of Cox's
proportional hazard multivariable regression model (Parmar
and Machin, 1995). The hazard function is given by k (t;
z)=Xo(t)exp(zf), in which z is a vector ofcovariates and # the
corresponding vector of regression parameters (Kalbfleisch,
1980). The variables were categorised as follows: z=0 for
normal values of the biochemical markers (i.e. (upper
reference limit), and for limited disease, PS>80, male sex and
age(60 years; z=1 for extensive stage, PS< 80, female sex
and age>60 years. Increased marker values were categorised
according to clinically meaningful cut off points defined by
the factor of increase above the upper reference limit as z= 1
when>factor 1 and(factor 2 (of upper reference limits);
z=2 when>factor 2 and(factor 4; z=3 when>factor 4
and<factor 6; z=4 when>factor 6.
As the basic question was the prognostic influence of S-
NSE in SCLC a Cox model for this variable alone was
derived in the first phase of the analysis. Dummy variables
for centre oforigin were included to adjust for influence from
factors such as therapy and care. The centre contributing
most patients (C7, n = 149) was selected as baseline and the
centre influence thus represented by eight dummy variables.
Different models were investigated, first including S-NSE as a
continuous variable followed by categorisation of S-NSE
Table I Standardisation of performance status
ECOGIWHO Karnofsky Devisedfrom ECOGIWHO
0 100 100
1 80-90 85
2 60-70 65
3 40-50 45
4 20-30 25
(Simon and Altman, 1994) in stepwise increasing categories,
where the steps represent the integer part of factor ofincrease
above the upper reference limit. Finally, we evaluated the
previously reported categorisation into clinically convenient
groups (J0rgensen et al., 1988). The three other variables, S-
LDH, S-CEA and S-AP, were categorised similarly, and
individually included into the NSE model to see if addition of
one or more of these markers would result in the model
explaining more of the variation in the data. A significant
improvement in fit would be indicated by the likelihood ratio
test (Parmar and Machin, 1995). The other variables were
included in a structured way, first stage and PS and then age
and sex, for which previous investigations have shown minor
impact (Rawson and Peto, 1990). The final model thus
included both biochemical and clinical variables. A
significance level of 0.1 was set as the limit for inclusion
and exclusion ofsingle variables in the model. In the selection
between the models, the model which fitted the data best was
selected and differences between models assessed by the Wald
test applying a significant level of 0.05 (Parmar and Machin,
1995).
The Cox model requirement ofproportional death hazards
between prognostic categories was tested graphically by log
minus log survival plots. Based on the regression coefficients
in the final model we established an algorithm for prognostic
categorisation, and Kaplan-Meier plots (Kaplan and Meier,
1958) were calculated for groups of patients with different
prognostic scores.
Results
Pretreatment characteristics are listed in Tables II and III.
Median survival duration was 267 days. Pretreatment S-NSE
was increased in 81% ofthe patients. S-LDH was available in
560 patients with data on both S-NSE and S-LDH, of which
S-NSE was increased in 81% compared with 54% increased
S-LDH values. The median age varied from 58 to 69 years.
Male sex was predominant (69-95%), but with regional
differences. Extensive disease was found in 56% of the
patients (range 43-70%), and poor PS was present in 38%
of all patients. Kaplan-Meier plots of survival on 770
patients from the nine centres are shown in Figure 1.
Seventeen patients were excluded because of lack of data
on status (dead or censored) or on survival.
S-NSE had a significant influence on survival when
investigated as a continuous as well as a categorised
variable. Reducing the 74 categories to five (0-4) improved
the fit significantly (P<0.0001), and identified five classes
with significantly different survival (Figure 2). Values
>250 Mg I` were rarely seen (Figure 3). Evaluation of the
S-NSE classes as separate variables did not change the model
(P=0.5) (Table IV). For the following analyses S-NSE was
consequently assessed as a categorised variable with the
previously identified cut-off points.
Table H Pretreatment characteristics and survival in patients with SCLC
Survival (days)
Age (years) Quantile
Centre n ED(%) Male sex(%) Median Range PS<80 50th 25th-75th
C1 121 64 69 64 34-77 42 304 150-417
C2 55 62 95 62 51-86 55 163 62-387
C3 48 65 69 63 40-79 35 332 151-489
C4 94 61 59 58 24-74 60 467 240-540
C5 86 43 70 63 38-77 28 285 175-468
C6 108 50 78 63 36-83 33 291 148-459
C7 149 48 90 60 33-74 34 298 187-453
C8 89 57 92 61 37-76 13 203 98-273
C9 37 70 78 59 39-72 NA 268 131-390
Total 787 56 78 62 24-86 38 263 140-399
C1, Cancer Medicine Research Unit, St James's University Hospital; C2, Hospitlal NS Sonsoles; C3, Bispebjerg Hospital;
C4, Institute ofTuberculosis and Pulmonary Diseases, Warsaw; C5, Finsen Center; C6, Dijkzigt Hospital; C7, Institute Jules
Bordet; C8, Hospital de Cruces; C9, St Ann's Hospice.Neuron specific enolase in small cell lung cancer
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Table III Pretreatment characteristics of laboratory measurements in SCLC
S-NSE S-LDH S-CEA S-AP
Quantile Quantile Quantile Quantile
Centre 50th 25th-75th % 50th 25th-75th % 50th 25th-75th % 50th 25th-75th %
C1 2.5 1.0-3.0 82 0.8 0.6-1.4 42 1.0 0.5-8.1 50
C2 3.8 1.4-7.4 85 0.9 0.8-1.6 47 - - - -
C3 3.5 2.0-6.1 88 1.1 0.8-1.5 61 - - 0.8 0.6-1.3 34
C4 1.8 1.3-5.2 86 - - - 0.6 0.3-1.9 35 0.7 0.6-1.1 28
C5 1.9 1.1-4.7 75 1.0 0.7-1.7 50 0.7 0.4-1.8 44 0.8 0.7-1.0 25
C6 2.2 1.3-5.3 82 0.9 0.8-1.2 39 - - - -
C7 2.2 1.3-3.9 77 1.4 0.9-1.9 69 - -
C8 2.3 1.3-5.0 80 - - 0.8 0.5-1.8 38 -
C9 1.9 0.9-4.5 62 0.8 0.6-1.4 30 - - - -
Total 2.2 1.3-5.6 81 1.0 0.8-1.6 53 0.7 0.4-3.2 43 0.8 0.6- 1.1 33
Median, quantiles and percentage increased variables from nine centres, Cl to C9.
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Figure 3 Histogram showing the distribution of S-NSE. Values
>20 (i.e. >250lig 1-1) only occurred in 2.3% of the patients.
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Figure 1 Life tables on 770 patients from the nine centres.
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Figure 2 Kaplan-Meier plots on 770 patients as related to
pretreatment S-NSE. Median survival for the groups were in
years: 1.07, 0.95, 0.80, 0.66 and 0.50 year. The number of
patients, n groups, were 145, 197, 170, 75 and 178. At risk after 2
years were: 20, 13, 10, 2 and five patients.
Next, the influence of S-LDH was investigated on the 560
patients with data available. The NSE-model was improved
by addition of S-LDH (P<0.005), whereas S-AP had no
significant influence (RR= 1.21), and S-CEA was without
influence at all (RR= 1.21). Stage ofdisease was included and
possessed significant influence (P<0.01) (Table V). Data on
PS were available in 500 patients, and addition of PS
significantly improved the model (P<0.0001). S-LDH could
now be excluded without loss of information (P =0.153)
(Table VI). Neither age nor sex had significant influence on
survival in any of the analyses. Exclusion of S-LDH enabled
Table IV Cox model including S-NSE and eight dummy variables
for centre of therapy in 770 patients with SCLC
Model S-NSE ,B LL LR X2(LR)
Continuous 1.4-924* 0.0036 -3879.20
-0.96 P>0.35
Categorical 0-73 0.0452 -3878.11
score
-22.14 P<0.0001
0-4 0.2633 -3867.64
-0.46 P=0.50
Separate NSE-1 0.2607
variables NSE-2 0.5003 -3876.42
NSE-3 0.8605
NSE-4 1.0383
First S-NSE as a continuous variable, then stepwise (integer division
with upper reference limit), third after collecting steps, finally a model
with steps as separate variables. LL, log liklihood; LR, likelihood ratio
test. *Pgl-1
establishment of a model based on 674 patients with data on
S-NSE, stage and PS. Dummy variables adjusting for the
impact of individual centre characteristics were included in all
models, but are only shown in Table VII. No significant
interaction between the influences of S-NSE, stage and PS
could be proved and the prognostic assumption was well
fulfilled for all three. Relative risks for the variables are given
in Table VII.
A prognostic index (PI) was established combining the
information from the three variables into a simple algorithm:
PI ZNSE +Z.tage+2zps. Based on Kaplan -Meier plots on the
resulting eight groups, four prognostic categories could be
established: good (PI =0), inter A (PI= 1-2), inter B
(PI = 3-6), poor (PI =7) (Table VIII, Figure 4).
(I)
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Table V Cox models before and after inclusion of S-LDH and stage
Model Score p LL LR 2
S-NSE 0- 14 0.2718 -2624.86 - -
-10.41 P<0.005
S-NSE 0-4 0.1946 -2619.65
S-LDH 0-4 0.2237
-7.36 P<0.01
S-NSE 0-4 0.1642
S-LDH 0-4 0.1959 -2615.97
Stage 0-1 0.2799 )
n= 560 patients (from seven centres, i.e. six dummy variables - not
shown). LL, log likelihood; LR, likelihood ratio test.
Table VI Cox model before and after inclusion of PS
Model Score ,B LL LR y2(LR)
S-NSE 0-4 0.1718
S-LDH 0-4 0.1683 -2297.30
Stage 0- 1 0.2825
-30.16 P<0.0001
S-NSE 0-4 0.1782
S-LDH 0-4 0.1066 -2282.22
Stage 0-1 0.1780
PS 0- 1 0.5879
2.04 P=0.153
S-NSE 0-4 0.2135
Stage 0-1 0.1896 -2283.24
PS 0- 1 0.6110
n= 500 patients (from six centers, i.e. five dummy variables - not
shown). LL, log likelihood; LR, likelihood ratio test.
Table Vm Distribution of 674 patients into groups defined by a
prognostic index based on S-NSE, stage and PS
Survival
Index PI n % Median (days) Two years (%)
0 57 8 468 22
1-2 192 34 362 14
3-6 285 46 256 6
7 81 12 124 1
Patients at risk given as 2 years' survival.
n
Good 8%
InterA 34%
Inter B 46%
Poor 12%
0 1 2 3 4
Years
Figure 4 Kaplan-Meier plots on 674 patients as related to
prognostic index-based S-NSE, PS and stage. Patients under risk
year 0-4: PI 0, 57, 38, 10, 5, 3 patients; PI 1-2, 192, 103, 25, 9, 4
patients; PI 3-6, 285, 74, 15, 4, 1 patients; PI 7, 81, 11, 1, 0, 0
patients.
Table VII Cox model including S-NSE, stage and PS based on 674
patients from eight centres (i.e. seven dummy variables)
Model Score ,B f/s.e.(,) RR
NSE 0-4 0.2116 6.49 1.24
Stage 0-1 0.2303 2.44 1.26
PS 0- 1 0.4871 5.32 1.63
Cl 0- 1 -0.0075 -0.06*
C2 0- 1 -0.3612 2.01*
C3 0-1 -0.1620 -0.78*
C4 0- 1 -0.5273 -3.68 0.59
C5 0- 1 -0.0997 0.67*
C6 0- 1 -0.0940 -0.65*
C8 0- 1 0.5644 3.54 1.76
s.e., standard error; RR, relative rate. * Not significant.
Discussion
As far as we know, this is the first meta-analysis on the
prognostic influence of S-NSE in SCLC. The investigation
shows that S-NSE is among the most influential prognostic
factors in this disease, and it seems to contain the
information given by the other routine variables. The
prognostic impact of S-NSE has previously been identified
in two multivariable studies evaluating S-NSE as a
categorised (J0rgensen et al., 1988) or a dichotomised
variable (Johnson et al., 1993) both including strong
prognostic variables such as PS and stage of disease, and
various biochemical variables. The present investigation in a
large population extending over more than one centre proved
the place of S-NSE in the establishment of a prognostic
index.
In spite of different staging procedures at the nine centres,
stage of disease had significant influence in the Cox model
and could not be ignored in the prognostic stratification of
patients with SCLC. The prognostic impact of stage, as well
as that of S-NSE, was unaffected by the influence of the
centre of origin variables. The influence of PS in the Cox
model changed, probably reflecting intercentre differences in
assessment of PS as well as the varying influence of PS in
relation to treatment. A great variety of treatment regimens
was used in this series so a direct investigation of treatment
impact on the prognosis was not possible-and not the aim of
this study.
About 80% of the S-NSE values were increased, and
there were no major differences in this ratio among the nine
centres. Early reports presented lower diagnostic sensitivity
(Carney et al., 1982), probably owing to the use of early and
individually developed immunohistochemical methods with
varying y-enolase specificity. S-NSE is positively correlated
to disease extent (Akoun et al., 1985; Cooper et al., 1985;
Gomm et al., 1988; Harding et al., 1990), and the
composition of a study patient population may therefore
influence the fractions of increased values. In this, as in a
previous Cox analysis, we found correlation between the
prognostic influence of S-NSE and S-LDH, reflecting that
the two variables partly carry the same clinical information.
If S-NSE is excluded from the model, S-LDH will be the
most influential biochemical factor. The importance of S-
LDH is in agreement with previous reports (Osterlind et al.,
1986; Cerny et al., 1987). Being increased in only 54% of
serum samples at the time of diagnosis, S-LDH is a less
sensitive prognostic determinant than S-NSE, especially in
limited stage disease.
The prognostic influence of PS and stage of disease in
SCLC has been recognised for about 20 years (Edmonson et
al., 1976; Cohen et al., 1979). Although stage had significant
influence in this investigation, its influence was weaker than
that of PS and S-NSE supporting the old idea that a
reasonable prognostic stratification is possible without data
on stage of disease (Cohen et al., 1981; Souhami et al., 1985;
Osterlind et al., 1986; Cerny et al., 1987; Vincent et al.,
1987).
Serum alkaline phosphatase possessed negligible influence
in this investigation. This is not, however, contradictory to
previous reports (Souhami et al., 1985; Rawson and Peto,Neuron specific enolase in small cell lung cancer
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1990), since the latter did not include S-LDH or S-NSE,
which both have a stronger relationship to the prognosis.
Serum carcinoembryonic antigen may have a weak relation-
ship to survival when investigated by the use of univariate
statistical methods, but both this and previous analyses
(J0rgensen et al., 1988) clearly prove that this component has
no place in a panel of prognostic markers in this disease.
Lack of prognostic influence of sex and age is in agreement
with previous studies, although a more favourable outlook
for female patients, especially (in terms of) long-term
survival, has been observed in a few series (Osterlind et al.,
1986; Wolf et al., 1991).
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